All In Biotech

Drug Trial Radar · NCT01906879

Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection

Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial

Last checked: Nov 19, 2026Latest source record: Jun 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,620 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,620

Planned (sponsor's estimate)

Start

Jun 2013

Primary completion

Dec 2017

Study completion Dec 2017

Sponsor

Lead sponsor
National Taiwan University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Whether non-bismuth quadruple therapy (concomitant therapy) is more effective than bismuth quadruple therapy or triple therapy for 14 days remains unknown. Therefore, we aim to compare the eradication rates and long term re-infection rates of quadruple therapy for 10 days versus non-bismuth quadruple therapy for 10 days vs. triple therapy for 14 days. Methods: This will be a multi-center, open labeled, randomized control trial Patients: H. pylori infected patients who have willingness to receive eradication therapy Testing for H. pylori infection Before First Line Ttreatment (1)Any two positive of rapid urease test, histology, serology and culture or a positive UBT will be considered as H. pylori infected After First Line Treatment: C13-Urea breath test will be used to assess the existence of H. pylori 6-8 weeks after first line therapy. Long term reinfection: C13- Urea breath test will be used to assess the recurrence of H. pylori 1 year after eradication therapy

Conditions

  • Helicobacter Pylori Infection

Interventions

  • triple, quadruple, non-bismuth quadruple therapyDrug

    triple therapy, quadruple therapy, non-bismuth quadruple therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication rate for H. pyloriTime frame: 6 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Chiayi Christian Hospital

    Chiayi City, Taiwan · Recruiting

  • National Taiwan University Hospital, Hsinchu Branch

    Hsinchu, Taiwan · Recruiting

  • E- DA Hospital and I-Shou University

    Kaohsiung City, Taiwan · Recruiting

  • Kaohsiung Medical University Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Ming-Shiang Wu

    Taipei, Taiwan · Recruiting

  • Mackay Memorial Hospital, Taipei

    Taipei, Taiwan · Recruiting

  • Taipei Medical University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • Mackay Memorial Hospital, Taitung

    Taitung, Taiwan · Recruiting

  • National Taiwan University Hospital, Yun-Lin Branch

    Yun-Lin County, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.